The impact of race on response to RAAS inhibition.

Thomas W. Wallace, Mark H. Drazner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Retrospective analyses of the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator Heart Failure Trials (V-HeFT) have addressed the question of whether angiotensin-converting enzyme (ACE) inhibitors are equally efficacious in black patients and white patients with heart failure. In SOLVD, there was no ethnic difference in the efficacy of enalapril for reducing mortality and preventing the development of heart failure, but enalapril was more effective in whites in reducing hospitalizations. In V-HeFT II, enalapril was more efficacious than the combination of isosorbide dinitrate and hydralazine in whites in reducing mortality, but not in blacks. However, the combination of isosorbide dinitrate and hydralazine may be particularly advantageous in black patients as suggested by V-HeFT I and the recent African American Heart Failure Trial. In aggregate, the available data suggest that ACE inhibitors should remain a cornerstone of therapy for heart failure with a reduced ejection fraction in white patients and black patients.

Original languageEnglish (US)
Pages (from-to)72-77
Number of pages6
JournalCurr Heart Fail Rep
Volume2
Issue number2
StatePublished - Aug 2005

Fingerprint

Heart Failure
Enalapril
Vasodilator Agents
Left Ventricular Dysfunction
Angiotensin-Converting Enzyme Inhibitors
Mortality
African Americans
Hospitalization
Retrospective Studies
isosorbide-hydralazine combination
hydroquinone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

The impact of race on response to RAAS inhibition. / Wallace, Thomas W.; Drazner, Mark H.

In: Curr Heart Fail Rep, Vol. 2, No. 2, 08.2005, p. 72-77.

Research output: Contribution to journalArticle

Wallace, Thomas W. ; Drazner, Mark H. / The impact of race on response to RAAS inhibition. In: Curr Heart Fail Rep. 2005 ; Vol. 2, No. 2. pp. 72-77.
@article{0ec1cf44188145db9805ae0589ee0739,
title = "The impact of race on response to RAAS inhibition.",
abstract = "Retrospective analyses of the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator Heart Failure Trials (V-HeFT) have addressed the question of whether angiotensin-converting enzyme (ACE) inhibitors are equally efficacious in black patients and white patients with heart failure. In SOLVD, there was no ethnic difference in the efficacy of enalapril for reducing mortality and preventing the development of heart failure, but enalapril was more effective in whites in reducing hospitalizations. In V-HeFT II, enalapril was more efficacious than the combination of isosorbide dinitrate and hydralazine in whites in reducing mortality, but not in blacks. However, the combination of isosorbide dinitrate and hydralazine may be particularly advantageous in black patients as suggested by V-HeFT I and the recent African American Heart Failure Trial. In aggregate, the available data suggest that ACE inhibitors should remain a cornerstone of therapy for heart failure with a reduced ejection fraction in white patients and black patients.",
author = "Wallace, {Thomas W.} and Drazner, {Mark H.}",
year = "2005",
month = "8",
language = "English (US)",
volume = "2",
pages = "72--77",
journal = "Current Alzheimer Research",
issn = "1531-0035",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The impact of race on response to RAAS inhibition.

AU - Wallace, Thomas W.

AU - Drazner, Mark H.

PY - 2005/8

Y1 - 2005/8

N2 - Retrospective analyses of the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator Heart Failure Trials (V-HeFT) have addressed the question of whether angiotensin-converting enzyme (ACE) inhibitors are equally efficacious in black patients and white patients with heart failure. In SOLVD, there was no ethnic difference in the efficacy of enalapril for reducing mortality and preventing the development of heart failure, but enalapril was more effective in whites in reducing hospitalizations. In V-HeFT II, enalapril was more efficacious than the combination of isosorbide dinitrate and hydralazine in whites in reducing mortality, but not in blacks. However, the combination of isosorbide dinitrate and hydralazine may be particularly advantageous in black patients as suggested by V-HeFT I and the recent African American Heart Failure Trial. In aggregate, the available data suggest that ACE inhibitors should remain a cornerstone of therapy for heart failure with a reduced ejection fraction in white patients and black patients.

AB - Retrospective analyses of the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator Heart Failure Trials (V-HeFT) have addressed the question of whether angiotensin-converting enzyme (ACE) inhibitors are equally efficacious in black patients and white patients with heart failure. In SOLVD, there was no ethnic difference in the efficacy of enalapril for reducing mortality and preventing the development of heart failure, but enalapril was more effective in whites in reducing hospitalizations. In V-HeFT II, enalapril was more efficacious than the combination of isosorbide dinitrate and hydralazine in whites in reducing mortality, but not in blacks. However, the combination of isosorbide dinitrate and hydralazine may be particularly advantageous in black patients as suggested by V-HeFT I and the recent African American Heart Failure Trial. In aggregate, the available data suggest that ACE inhibitors should remain a cornerstone of therapy for heart failure with a reduced ejection fraction in white patients and black patients.

UR - http://www.scopus.com/inward/record.url?scp=24044498345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044498345&partnerID=8YFLogxK

M3 - Article

C2 - 16036054

AN - SCOPUS:24044498345

VL - 2

SP - 72

EP - 77

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1531-0035

IS - 2

ER -